Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

15
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
15
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Targeting the oxidative microenvironment with a tannic acid-modified manganese dioxide nanozyme loaded with Honokiol nanoplatform to activate sirtuin 3-mediated deacetylation for alleviating cerebral ischemia-reperfusion injury.

Journal of nanobiotechnology·2026
Same author

Dysregulated connectivity configuration of functional network model in first-episode, treatment-naive adolescents with major depressive disorder.

BMC psychiatry·2026
Same author

Socializing smartly: Differentiated health benefits from online and place-based in-person socialization among older adults in urban China.

Health & place·2026
Same author

Technological and safety characterization of <i>Staphylococcus saprophyticus</i> NHY-25 isolates from high-temperature <i>Daqu</i>, a starter of <i>Jiangxiangxing Baijiu</i>.

Food science and biotechnology·2026
Same author

Social Infrastructures for Healthy Aging: The Intersection of Space, Activity, and Community Engagement in China's Urban Neighborhoods.

Research on aging·2026
Same author

Circulating extracellular vesicles as systemic mediators of cardiac aging: Mechanisms, biomarkers, and therapeutic perspectives.

Ageing research reviews·2026

Related Experiment Video

Updated: Jul 17, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.3K

Myocardial Metabolic Reprogramming in HFpEF.

Zihui Zhang1, Mingchu Sun1, Wenhua Jiang1

  • 1Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, Shaanxi, 710072, People's Republic of China.

Journal of Cardiovascular Translational Research
|August 31, 2023
PubMed
Summary
This summary is machine-generated.

Heart failure with preserved ejection fraction (HFpEF) involves cardiac mitochondrial dysfunction and metabolic reprogramming. Targeting these metabolic changes offers a promising therapeutic strategy for HFpEF treatment.

Keywords:
Heart failure with preserved ejection fractionHeart failure with reduced ejection fractionMetabolic reprogrammingMitochondrial dysfunction

More Related Videos

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.2K
Assessing Cardiac Reprogramming using High Content Imaging Analysis
06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

1.3K

Related Experiment Videos

Last Updated: Jul 17, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.3K
Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.2K
Assessing Cardiac Reprogramming using High Content Imaging Analysis
06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

1.3K

Area of Science:

  • Cardiology
  • Metabolic research
  • Biochemistry

Background:

  • Heart failure (HF) is a major global health burden, with HF with preserved ejection fraction (HFpEF) affecting over half of patients.
  • Current HFpEF treatments primarily manage symptoms, lacking targeted therapies due to incomplete understanding of its mechanisms.
  • Cardiac metabolic reprogramming is a compensatory response to stress in HF, but its specific role in HFpEF needs further investigation.

Purpose of the Study:

  • To review the current understanding of cardiac mitochondrial dysfunction in HFpEF.
  • To summarize the role of cardiac metabolic reprogramming in the pathophysiology of HFpEF.
  • To highlight potential therapeutic strategies targeting metabolic pathways for HFpEF treatment.

Main Methods:

  • Literature review focusing on cardiac metabolism and HFpEF.
  • Synthesis of findings on mitochondrial function and metabolic shifts in HFpEF.
  • Analysis of emerging therapeutic targets related to metabolic reprogramming.

Main Results:

  • HFpEF is characterized by significant cardiac mitochondrial dysfunction.
  • Metabolic reprogramming, including altered substrate utilization, is a key feature of HFpEF.
  • These metabolic alterations contribute to pathological cardiac remodeling in HFpEF.

Conclusions:

  • Mitochondrial dysfunction and metabolic reprogramming are central to HFpEF pathophysiology.
  • Targeting metabolic pathways presents a novel and promising therapeutic avenue for HFpEF.
  • Further research into metabolic interventions could lead to effective HFpEF treatments.